Nvidia, Eli Lilly to spend $1 billion over five years
Digest more
Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...
Eli Lilly came to the 44 th annual JP Morgan Healthcare Conference bolstered by a strong year. 1 While the looming patent cliff still impacts that company’s upcoming strategy, Lilly found itself in a ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.
France's Finance Ministry said on Monday it had received no formal request for investment approval regarding French biotech ...
Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...
The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...
After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition ...
Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback